Extract

Current rifampicin/ethambutol/azithromycin regimens for the treatment of Mycobacterium avium complex pulmonary disease (MAC-PD) are long, toxic and yield relatively poor outcomes [1]: a meta-analysis lumping nodular bronchiectatic disease and fibro-cavitary disease reported a 65% prolonged culture conversion rate; following initially successful treatment, recurrence rates of 30% have been reported [2].

中文翻译：

---

利福平治疗鸟分枝杆菌复合型肺病无作用需杀菌消毒药物：一个观点

提炼

目前用于治疗鸟分枝杆菌复合型肺病 (MAC-PD) 的利福平/乙胺丁醇/阿奇霉素方案时间长、毒性大且疗效相对较差 [1]：一项将结节性支气管扩张病和纤维空洞病合并的荟萃分析报告称 65 ％延长的培养物转化率；据报道，在最初成功治疗后，复发率为 30% [2]。